Medical Mycology

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp

Retrieved on: 
Wednesday, September 29, 2021
OPC, Biotechnology, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SOC, Tablet, Candidiasis, Standard of care, Rifian, UAB, Multiplicity of infection, Infection, NASDAQ, FDA, Canker, EC, Population, IV, Augusta University, Drug of last resort, Medical Mycology, FURI, FACP, IC, VVC, Esophageal candidiasis, University of Alabama, Joint, Fungemia, Interim analysis, University, IA, MPH, Trial of the century, Risk, Wake Forest Baptist Medical Center, Azole, Safety, QIDP, Mycosis, GLOBE, Pharmaceutical industry, Birth control, Paint

The compilation and disease subset analyses are being presented during IDWeek, taking place virtually September 29 October 3, 2021.

Key Points: 
  • The compilation and disease subset analyses are being presented during IDWeek, taking place virtually September 29 October 3, 2021.
  • Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI) Peter G. Pappas, M.D., University of Alabama at Birmingham (UAB)
    Oral Presentation New Findings in Medical Mycology: O-25.
  • Of the 74 patients treated with oral ibrexafungerp 62.1% showed complete or partial response, 24.3% achieved stable disease, 6.8% showed progressive disease, and 5.4% were indeterminate.
  • The presentation highlights a sub-analysis of eight patients with Candida bone and joint infections from the Phase 3 FURI study.

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections

Retrieved on: 
Thursday, September 23, 2021
Biotechnology, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Tablet, UAB, NASDAQ, FDA, IV, Augusta University, Drug of last resort, Medical Mycology, FURI, FACP, IC, VVC, Esophageal candidiasis, University of Alabama, Fungemia, Interim analysis, University, IA, Canker, MPH, Wake Forest Baptist Medical Center, QIDP, Mycosis, GLOBE, Pharmaceutical industry, Paint

The data from these three presentations provide a deeper understanding of ibrexafungerps activity against a broad spectrum of fungal infections caused by Candida species, including azole- and echinocandin-resistant strains.

Key Points: 
  • The data from these three presentations provide a deeper understanding of ibrexafungerps activity against a broad spectrum of fungal infections caused by Candida species, including azole- and echinocandin-resistant strains.
  • We are encouraged by the interim results of the study as we work toward the goal of making ibrexafungerp available to patients with serious fungal infections in the U.S. and around the world.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.